Skip to main content

COVID 19 Updates from RheumNow

COVID-19 Systemic Involvement

The presentations of the COVID-19 infection have been clearly chronicled with the worrisome onset of sore throat, dry cough, loss of smell and taste with fevers, myalgias, fatigue and the worrisome progression of pulmonary involvement in a minority.  Lab findings may include a leukocytosis, lymph

ACR COVID-19 Guidance for Rheumatic Disease Patients

On April 11th, the ACR Board of Directors approved a COVID-19 guidance document written by an ACR task force charged with updating and clarifying recommendations for rheumatologists and rheumatic disease patient management during the current COVID-19 crisis.

Post 9/11 Autoimmune Disease Risk

The 9/11/01 terrorist attach on the World Trade Center (WTC)  resulted in at least 2,977 fatalities, over 25,000 injuries, and caused at least $10 billion in infrastructure and property damage.  Arthritis & Rheumatology reports that dust cloud exposure among responders and PTSD among

RheumNow Podcast – The Beginning of Something Else (4.10.20)

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Coagulopathy and Antiphospholipid Antibodies with Covid-19

The New England Journal of Medicine has featured a report of three COVID infected patients, who developed peripheral and central infarcts with a antiphospholipid antibodies. 

Urgent or Not

Rheumatologic practice has been turned upside down as a consequence of the COVID-19 crisis. 

TNR - Grand Rounds: Safety of Biologics & New Agents

On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures.  The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".

Incubation Period for COVID-19

The incubation period for coronavirus disease 2019 (COVID-19) has important implications for surveillance and control activities. The Annals of Internal Medicine reports a pooled analysis of confirmed COVID-19 cases January 4, 2020 and February 24, 2020.

COVID-19 Susceptibility: Why Do Some Become So Ill?

Why are some people with the SARS-CoV-2 coronavirus that causes COVID-19 so ill while others barely notice the infection?

NICE Guidelines on Managing Rheumatologic Conditions During COVID-19 Pandemic

On April 3rd, the National Institute for Health and Care Excellence (NICE) in the UK, published a rapid guideline for managing children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection.

COVID Town Hall Meeting for Rheumatology

On Thursday, April 2nd, RheumNow hosted its' first Town Hall Meeting for Rheumatologist, with this 90 minute discussion devoted to the COVID-19 crisis as it affects Rheumatologists. 

RheumNow Podcast – Pandemic Numbers (4.3.20)

Dr. Jack Cush reviews the news on COVID-19 and FDA actions this past week. Be sure to check out:

Social

ACR has published COVID-19 Recs -American College of Rheumatology Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID‐19 Pandemic by Mikuls Johnson Fraenkel Arasaratnam Baden Bermas Chatham https://t.co/wwpslcLXx2

Dr. John Cush RheumNow( View Tweet)

2 months 1 week ago
HCQ fails to prevent severe COVID19 in 17 SLE pts (w/ CKD, GN, APL, 12 pred, 7 on immunosuppressants).14 hospitalized, 13 viral pneumonia, 11 respiratory failure, 5 ARDS; 3 ARF. Despite good HCQ levels, 2 died, 5 on ventilator, 36% D/C, 1/2 still hosp. https://t.co/e0qLGtF6Nj

Dr. John Cush RheumNow( View Tweet)

2 months 1 week ago
Health Canada issued a safety alert noting Chloroquine & hydroxychloroquine can have serious toxicities & should only be used under a physicians supervision. Due o concern that some may be directly buying/using CQ/HCQ to treat/prevent COVID-19 https://t.co/ksxveHADZX

Dr. John Cush RheumNow( View Tweet)

2 months 1 week ago
Sanofi announced early results of phase 2 trial of IL6 inhibitor, sarilumab, showing benefit only in Critical COVID-19 pts. 457 pts given IV Kevzara 400 mg vs 200 mg vs PBO , high dose had fewer deaths (32 v 46 v 55%) & more D/C (53 v 39 v 41%). https://t.co/6q21qJNj2C

Dr. John Cush RheumNow( View Tweet)

2 months 1 week ago
On April 24, FDA issued a Drug Safety Communication stating HCQ and CQ have not been shown to be safe and effective in COVID-19 and that HCQ/CQ should not be used outside of hospitalized or pts in clinical trials. https://t.co/l2DNBhhvTR

Dr. John Cush RheumNow( View Tweet)

2 months 1 week ago
The RheumNow Podcast is up! "In times of Trouble". Watch it here>> https://t.co/gapTwq3REW or listen to the podcast on iTunes or SoundCloud>> https://t.co/dpoCoX8qBR

Dr. John Cush RheumNow( View Tweet)

2 months 1 week ago
The RheumNow Podcast is up! "In times of Trouble". ABA and DM, Zostavax fails, 3d Doubling rate, population testing, HCQ in COVID; Watch it here>> https://t.co/gapTwq3REW or listen to the podcast on iTunes or SoundCloud>> https://t.co/dpoCoX8qBR

Dr. John Cush RheumNow( View Tweet)

2 months 2 weeks ago
There’s a saying that anyone driving faster than you is crazy and anyone driving slower doesn’t know how to drive. Similar with COVID-19: anyone taking more precautions than you has an anxiety issue and anyone taking fewer is an idiot.

Adam Cifu adamcifu( View Tweet)

2 months 2 weeks ago
Dr C Kershaw @UTSWNews grand rounds on ventilation in #COVID19 Why putting pts in prone position might help with ARDS ⁦@RheumNow⁩ https://t.co/I0AOx72Jwl
2 months 2 weeks ago
ACR Guidance for Rheumatic Disease during COVID-19 pandemic #Rheumatology @RheumNow https://t.co/vHav6g4p6Q
Maeve Gamble MaeveGamble( View Tweet)
2 months 2 weeks ago
×